Images List Premium Download Classic

Leukemia

Leukemia-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
Janssen Biotech, Inc.
November 09, 2017 - N°20170320961

The present invention relates to combination therapies with anti-cd38 antibodies.
Methods for manipulating phagocytosis mediated by cd47
The Board Of Trustees Of The Leland Stanford Junior University
November 09, 2017 - N°20170320945

Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e. G. Circulating hematopoietic cells, bone marrow cells, acute leukemia cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating ...
Quinoline carboxamides for use in the treatment of leukemia
Active Biotech Ab
November 09, 2017 - N°20170319568

A compound of formula (i) or a pharmaceutically acceptable salt thereof, for use in the treatment of leukemia.
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Markers of poor prognosis acute myeloid leukemias (amls) and uses thereof
Rsem, Limited Partnership
October 26, 2017 - N°20170307619

Genes exhibiting specific mutational and/or transcriptional patterns in poor prognosis amls, such as evi1-rearranged acute myeloid leukemias (evi1-r amls), relative to other types of amls and/or normal cd34+ cells, are disclosed. The use of these mutational and/or transcriptional patterns, for example the expression level of the prkc apoptosis wt1 regulator (pawr) gene, for the diagnosis ...
Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (irak4) in cancers characterized by rearrangements in the mixed ...
Northwestern University
October 26, 2017 - N°20170305901

Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (mll-r), including mll-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (irak4).
Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
October 26, 2017 - N°20170304441

Highly effective combinations of a compound of formula a (a pi3kδ selective inhibitor) and anti-cd20 antibodies are provided herein for the treatment and amelioration of pi3kδ and/or cd20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination ...
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in ...
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
October 19, 2017 - N°20170298449

The invention provides arrays, systems, devices, methods, computer-readable media and kits that enable expression-based classification of b-precursor acute lymphoblastic leukemia (all) as being either responsive or non-responsive to tyrosine kinase inhibitor mono or co-therapy.
Use of clonal evolution analysis for ibrutinib resistance in chronic lymphocytic leukemia patients
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
October 19, 2017 - N°20170298441

The present invention generally relates to the methods and use of clonal evolution analysis of the kinetics and genetic alterations associated with the development of resistance to a therapy using whole-exome and deep targeted sequencing in treating patients in need thereof.
Use of agents for treating fat-related disorders
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
October 19, 2017 - N°20170298361

Use of agents that down-regulates an amount and/or activity of abelson murine leukemia viral oncogene homolog 1 (c-abl) or checkpoint kinase 1 (chk1) in the production of a medicament for treating obesity are disclosed.
Bispecific antibodies for use in stem cell transplantation
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
October 19, 2017 - N°20170298148

New monoclonal antibodies for use in pre-treatments prior to stem cell transplantations are disclosed. The antibodies may be used to kill malignant cells and/or stem cells prior to stem cell transplantation. The antibodies can be used for treating hematologic diseases and hematological malignancies, such as leukemia and mds. The antibodies of the invention might be multi- or bi-specific, such ...
N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
October 19, 2017 - N°20170298062

Disclosed are compounds useful as inhibitors of the wnt signalling pathway. Specifically, inhibitors of porcupine (porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the wnt signalling pathway, for example, in treating cancer, sarcoma, ...
Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
October 19, 2017 - N°20170298061

This invention relates to novel compounds. The compounds of the invention are kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of raf kinases, e. G., b-raf and c-raf. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of raf kinases, for example, cancer, sarcoma, melanoma, skin cancer, haematological tumors, ...
Rho associated kinase (rock) inhibitors and their use in treating disease
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
October 19, 2017 - N°20170296617

The present disclosure describes peptide inhibitors of rho-associtated-kinase (rock) and their use in treating disorders including heart failure, the leading cause of combined morbidity and mortality in the united states. An inhibitory polypeptide blocks rock1 activity in the presence of 1 mm atp. The binding epitope on rock1 was mapped using chemical cross-linking to the activation loop, a novel locus identifying ...
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods for diagnosis, prognosis and methods of treatment
Nodality, Inc.
October 05, 2017 - N°20170285027

This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of a cell present in a sample (e. G. Clinical sample) can be used in diagnosis or prognosis of a condition (e. G. Chronic lymphocytic leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic ...
Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
Cellectis
October 05, 2017 - N°20170283497

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a ror1 monoclonal antibody, conferring specific immunity against ror1 positive cells. The engineered immune cells endowed with such cars are particularly ...
Compounds and methods for kinase modulation, and indications therefor
Cellectis
October 05, 2017 - N°20170283423

In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of fms, kit, flt3, trka, trkb and trkc kinase protein. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of one or more of fms, ...
Poly(adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
Institute For Cancer Research D/b/a The Research Institute Of Fox Chase Cancer Center
October 05, 2017 - N°20170283402

Compounds that are not related to nad, and which target parp1-histone h4 interaction are provided, as well as compositions of these compounds, and methods for specific inhibition of poly(adp-ribose) polymerase 1 (parp-1) using these compounds are provided. These parp-1 inhibitors may be used to treat cancer in which parp-1 activation or biologic activity plays a role, including prostate cancer, ...
Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine ...
Oncoethix Gmbh
October 05, 2017 - N°20170281642

A method of treating acute myeloid leukemia or acute lymphoid leukemia in a mammal comprising the step of: administering a pharmaceutically acceptable amount of a thienotriazolodiazepine compound represented by the following formula (1): wherein r1 is alkyl having a carbon number of 1-4, r2 is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted ...
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
Cellectis
September 28, 2017 - N°20170275374

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a 5t4 monoclonal antibody, conferring specific immunity against 5t4 positive cells. The engineered immune cells endowed with such cars are particularly ...
N-pyridinyl acetamide derivatives as inhibitors of the wnt signaling pathway
Redx Pharma Plc
September 28, 2017 - N°20170275276

Disclosed are compounds useful as inhibitors of the wnt signalling pathway. Specifically, inhibitors of porcupine (porcn) are contemplated by the invention. In addition, the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the wnt signalling pathway, for example, in treating cancer, sarcoma, ...
Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
The Penn State Research Foundation
September 28, 2017 - N°20170274100

Non-aggregating resorbable calcium phosphosilicate nanoparticles (cpnps) are bioconjugated to targeting molecules that are specific for particular cells. The cpnps are stable particles at normal physiological ph. Chemotherapy and imaging agents may be integrally formed with the cpnps so that they are compartmentalized within the cpnps. In this manner, the agents are protected from interaction with the environment at normal physiological ...
Loading